![]() |
Sativex®: A Realistic Option for Advanced Cancer Pain?...
April 1, 2012 - Clinical , Featured , In the News / Politics By: Kathlynn Ferrer, Pharm.D. Candidate c/o 2013 – Nabiximols (Sativex®) is a buccal spray that has been approved for use in the UK, Spain, Germany, Denmark, New Zealand, and Canada. The active ingredients in this product are Tetrahydrocannabinol and Cannabidiol, two kinds of cannabinoids1. Cannabinoids are chemical compounds that stimulate cannabinoid receptors and are the… |
![]() |
Interview with: Mr. Phil Hecken, Director of Communicat...
April 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions By: Mahdieh Danesh Yazdi – In previous issues, we discussed prescription drug abuse and several bills currently on the floor of the NYS Legislature, sponsored by Sen. Hannon which addressed the issue. On February 7th, I sat down with Sen. Hannon’s director of communications, Mr. Phil Hecken, and his legislative aide, Mr. Timothy Broschardt to… |
![]() |
Eight Ways to Kick the Habit...
April 1, 2012 - Clinical , Professional Advice / Opinions By: Nagma Gargi, Pharm.D. Candidate c/o 2013 – Smoking cessation programs are extremely important in our society as increasing evidence emerges showing the correlation between smoking and the risk factors for various disease states. Thus as professionals it is our duty to educate ourselves first, then our patients. In this article, I want to discuss… |
![]() |
HMG-CoA Reductase Inhibitors And Memory Loss...
April 1, 2012 - Clinical , Featured By: Yufan (Frank) Liu, Pharm.D. Candidate c/o 2013 – Results of numerous epidemiological studies have indicated that having high serum cholesterol can lead to coronary heart disease (CHD). 1 More specifically having high LDL cholesterol puts patients at risk for angina and heart attack.2 To reduce this risk HMG-CoA reductase inhibitors, also known as statins,… |
![]() |
Counterfeit Prescription Medications: A Global Threat...
April 1, 2012 - Featured , In the News / Politics By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Counterfeit prescription medications are becoming a great concern for us. They have increased worldwide costs and endangered our public safety. Activities related to counterfeit drugs cost our healthcare system an estimated $75 billion in 2010. Many patients were seriously injured and died due to counterfeit medications.… |
![]() |
Jentadueto Approved by FDA for Type 2 Diabetes Mellitus...
March 1, 2012 - Clinical , In the News / Politics By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes. Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a… |
![]() |
FDA Makes Label Changes to Statins...
March 1, 2012 - Clinical , In the News / Politics By: Mohamed Dungersi – On February 28, the U.S. Food and Drug Administration (FDA) approved important safety label changes for the class of cholesterol-lowering drugs known as statins. Aligned with the FDA’s goal to provide the public with more information for the safe and effective use of statins, the agency made several modifications to the… |
![]() |
Link Revealed: PPI Usage, Smoking and Bone Fractures...
February 1, 2012 - Clinical , In the News / Politics By: Ebey P. Soman – Proton pump inhibitors (PPIs) are medications commonly prescribed to treat heartburn, acid reflux disease, and ulcers. Almost a vast majority of patients in the United States seem to be taking a PPI, either as a prescription or from over-the-counter (OTC). Researchers recently discovered associations between the long-term use of PPIs… |
![]() |
Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support. The main cause of this decreased BMD is inadequate calcium intake or absorption. The decreased BMD can cause diffuse lesions throughout the skeletal system and can… |
![]() |
Bydureon®: A Weekly Injection for Type 2 Diabetes Mell...
February 1, 2012 - Clinical , Featured , In the News / Politics By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise. Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide). It is the first once-a-week medication for T2DM in the market.… |
![]() |
Should Plan B Have an Age Restriction?...
February 1, 2012 - Professional Advice / Opinions By: Marie Huang – Back in December, the FDA was overruled by the presidential administration to make Plan B (levonorgestrel 1.5 mg) an over-the-counter (OTC) medication.1 We became interested in the matter, and asked our fellow students if Plan B should be available to people of all ages directly off of drugstore / supermarket shelves… |
![]() |
Hope on the Horizon: Chikungunya Vaccine Trial Begins!...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Ebey P. Soman – Since its discovery in Tanganyika (modern day Mozambique and Tanzania in Africa) in 1952, Chikungunya virus outbreaks have been documented in Africa, South Asia, and Southeast Asia. Due to recent globalization and increased travel, infection has also spread outside of tropical regions and even into western nations (such as the… |
![]() |
New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1 Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.… |
![]() |
FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans. Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack. On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for… |
![]() |
Greater Bone Loss in Post-Menopausal Women with HIV...
January 1, 2012 - Clinical , In the News / Politics By: Bibin Thomas, Long Island University, PharmD Candidate – Earlier in 2011, it was reported that that young and middle-aged HIV positive patients did not need to receive routine Bone Mineral Density (BMD) tests. BMD helps to identify patients who are at a high risk for bone fractures or weakened bone structures (and eventually need… |
![]() |
Alumni Spotlight: Making the Right Decisions...
January 1, 2012 - Featured , Professional Advice / Opinions By: Jim Fitzgerald, RPh – James Fitzgerald is a SUNY Buffalo School of Pharmacy graduate from the class of 1980. He is currently the supervising pharmacist at Pathmark Pharmacy of Baldwin in Long Island, New York. Mr. Fitzgerald is also a community pharmacy preceptor with St. John’s University and a longtime member of the Rho… |
![]() |
Xigris: A Worldwide Withdrawal...
January 1, 2012 - Clinical , In the News / Politics By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients. Drotrecogin alfa is a recombinant form of human activated protein C. The efficacy of drotrecogin alfa was… |
![]() |
Finding Your Niche in Pharmacy...
December 1, 2011 - Professional Advice / Opinions By: Nandini Puranprashad – As primary advocators of patient care, student pharmacists and pharmacists are well on their way in changing the public’s impression of us staying behind the counter at the corner drugstore doing nothing but “counting, licking, and sticking.” It is time to step out of the classroom and from behind the counters… |
![]() |
HIV Transmitted from a Living Organ Donor: NYC, 2009...
December 1, 2011 - Clinical By: Alisha Kumar, PharmD Candidate c/o 2012 – HIV transmission via organ transplantation is rare in the United States. However, after a public health investigation in 2010, a case of HIV transmission via kidney transplantation was confirmed. The kidney recipient had no history of sexually transmitted infections (STIs), injection drug use, sex with injection drug… |
![]() |
Faculty Spotlight: Dr. Charles R. Ashby...
December 1, 2011 - Featured , Professional Advice / Opinions By: Neal Shah – Dr. Ashby is a well-known Pharmacology professor for student pharmacists studying in their professional years. He graduated from the University of Louisville with a BA in Biology and Psychology in 1983. After obtaining his PhD in Pharmacology from the University of Louisville in 1987, he continued his education by obtaining a… |
![]() |
Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte… |
![]() |
In The News: TNF-Alpha Inhibitors Receive More Warnings...
October 1, 2011 - In the News / Politics By Ebey P. Soman – TNF-alpha inhibitors are drugs used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, as well as other disease states. These agents suppress the immune system and increase the risk of developing serious infections. Currently, there are five approved drugs in this category: • Adalimumab (Humira®, Abbott) • Certolizumab pegol… |
![]() |
Clinical Update: Heart Failure and Osteoporosis-Related...
October 1, 2011 - Clinical , Featured By: Mahdieh Danesh Yazdi – Heart failure is a condition in which the heart cannot pump blood efficiently to adequately perfuse tissues. It is often associated with serious consequences, such as kidney failure, liver dam-age, heart attack, and stroke. Patient care is focused on preventing these complications. Recently, attention has turned to other concerns: studies… |